PMID- 9079740
OWN - NLM
STAT- MEDLINE
DCOM- 19970813
LR  - 20200225
IS  - 0300-5623 (Print)
IS  - 0300-5623 (Linking)
VI  - 25
IP  - 1
DP  - 1997
TI  - Evaluation of epidermal growth factor receptor, transforming growth factor alpha, 
      epidermal growth factor and c-erbB2 in the progression of invasive bladder 
      cancer.
PG  - 9-17
AB  - INTRODUCTION: Determination of the risk of invasive bladder tumors progressing is 
      still imprecise due to the heterogeneous biological behavior of this neoplasm. 
      The goals of this study were to evaluate the patterns of expression of the 
      epidermal growth factor (EGF) system in invasive bladder cancer and to assess its 
      prognostic value. METHODS: This immunohistochemical study was performed using 
      fresh frozen tumor samples and a panel of monoclonal antibodies on a series of 43 
      invasive bladder cancers treated by cystectomy. RESULTS: EGF was detected in 45% 
      of the tumors and did not correlate with survival from bladder cancer. 
      Transforming growth factor alpha (TGF alpha) was expressed by 60% of the tumors 
      and correlated strongly with death from bladder cancer. Epidermal growth factor 
      receptor (EGF-R) expression was seen in 86% of cases and had no prognostic 
      significance. c-erbB2 was expressed in 50% of cases and was inversely related to 
      a poor prognosis. When EGF and TGF alpha were both expressed, there was little or 
      no expression of c-erbB2. CONCLUSION: The accumulation of several growth factors 
      and the relevant receptor are necessary for the progression of invasive bladder 
      cancers. They could be used as indicators of tumor aggressiveness.
FAU - Ravery, V
AU  - Ravery V
AD  - Service d'Urologie, Centre Hospitalier Universitaire Bichat, Paris, France.
FAU - Grignon, D
AU  - Grignon D
FAU - Angulo, J
AU  - Angulo J
FAU - Pontes, E
AU  - Pontes E
FAU - Montie, J
AU  - Montie J
FAU - Crissman, J
AU  - Crissman J
FAU - Chopin, D
AU  - Chopin D
LA  - eng
PT  - Journal Article
PL  - Germany
TA  - Urol Res
JT  - Urological research
JID - 0364311
RN  - 0 (Transforming Growth Factor alpha)
RN  - 62229-50-9 (Epidermal Growth Factor)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Transitional Cell/diagnosis/*metabolism/pathology
MH  - Disease Progression
MH  - Epidermal Growth Factor/*metabolism
MH  - ErbB Receptors/*metabolism
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Receptor, ErbB-2/*metabolism
MH  - Transforming Growth Factor alpha/*metabolism
MH  - Urinary Bladder Neoplasms/diagnosis/*metabolism/pathology
EDAT- 1997/01/01 00:00
MHDA- 1997/01/01 00:01
CRDT- 1997/01/01 00:00
PHST- 1997/01/01 00:00 [pubmed]
PHST- 1997/01/01 00:01 [medline]
PHST- 1997/01/01 00:00 [entrez]
AID - 10.1007/BF00941900 [doi]
PST - ppublish
SO  - Urol Res. 1997;25(1):9-17. doi: 10.1007/BF00941900.